UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)

Annals of oncology, 2005-01, Vol.16 (1), p.90-96

2005

Volltextzugriff (PDF)

A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index

British journal of cancer, 2005-11, Vol.93 (10), p.1098-1105

2005

Volltextzugriff (PDF)

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours

British journal of dermatology (1951), 2004-07, Vol.151 (1), p.238-241

2004

Volltextzugriff (PDF)

Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04–IFCT 00-01

Journal of clinical oncology, 2007-09, Vol.25 (25), p.3945-3951

2007

Volltextzugriff (PDF)

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes

Lung cancer (Amsterdam, Netherlands), 2005, Vol.47 (1), p.69-80

2005

Volltextzugriff (PDF)

Survival of Patients With Resected N2 Non–Small-Cell Lung Cancer: Evidence for a Subclassification and Implications

Journal of clinical oncology, 2000-08, Vol.18 (16), p.2981-2989

2000

Volltextzugriff (PDF)

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

British journal of cancer, 2000-07, Vol.83 (1), p.8-15

2000

Volltextzugriff (PDF)

Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials

Lung cancer (Amsterdam, Netherlands), 2006-03, Vol.51 (3), p.335-345

2006

Volltextzugriff (PDF)

Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer

The New England journal of medicine, 2004-01, Vol.350 (4), p.351-360

2004

Volltextzugriff (PDF)

Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin

Annals of oncology, 2005-04, Vol.16 (4), p.602-610

2005

Volltextzugriff (PDF)

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

Journal of clinical oncology, 2001-03, Vol.19 (6), p.1743-1749

2001

Volltextzugriff (PDF)

Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy should prophylactic cranial irradiation be reconsidered?

Cancer, 2001-06, Vol.91 (12), p.2394-2400

2001

Volltextzugriff (PDF)

Etoposide Plus Cisplatin With or Without the Combination of 4′-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study

JNCI : Journal of the National Cancer Institute, 2001-02, Vol.93 (4), p.300-308

2001

Volltextzugriff (PDF)

Routine molecular profiling of cancer: results of a one-year nationwide program of the French CooperativeThoracic Intergroup (IFCT) for advanced non-small cell lung cancer (NSCLC) patients

The Lancet (British edition), 2016, Vol.387, p.1415-1426

2016

Volltextzugriff (PDF)

Second-line treatment for advanced non-small cell lung cancer: A systematic review

Lung cancer (Amsterdam, Netherlands), 2006-02, Vol.51 (2), p.159-172

2006

Volltextzugriff (PDF)

Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients

Lung cancer (Amsterdam, Netherlands), 2001-02, Vol.31 (2-3), p.221-231

2001

Volltextzugriff (PDF)

Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2003-02, Vol.39 (2), p.131-138

2003

Volltextzugriff (PDF)

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

Journal of clinical oncology, 1994-02, Vol.12 (2), p.360-367

1994

Volltextzugriff (PDF)

Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data

British journal of cancer, 2001-07, Vol.85 (1), p.14-22

2001

Volltextzugriff (PDF)

Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: A systematic review of phase III trials

Lung cancer (Amsterdam, Netherlands), 2005-09, Vol.49 (3), p.289-298

2005

Volltextzugriff (PDF)

Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer

Cancer research (Chicago, Ill.), 1993, Vol.53 (1), p.61-66

1993

Volltextzugriff (PDF)

Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2000-09, Vol.29 (3), p.197-203

2000

Volltextzugriff (PDF)

Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer

Annals of oncology, 2004-01, Vol.15 (1), p.38-44

2004

Volltextzugriff (PDF)

Long Term Analysis of Survival in the European Randomized Trial Comparing Vinorelbine/Cisplatin to Vindesine/Cisplatin and Vinorelbine Alone in Advanced Non‐Small Cell Lung Cancer

The oncologist (Dayton, Ohio), 2001-01, Vol.6 (S1), p.8-11

2001

Volltextzugriff (PDF)

Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer

British journal of cancer, 2004-08, Vol.91 (3), p.430-433

2004

Volltextzugriff (PDF)

1 – 25 von 232

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(217)
Mit Volltextzugriff
(178)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(215)
Life Sciences & Biomedicine
(200)
Humans
(163)
Biological And Medical Sciences
(131)
Female
(114)
Medical Sciences
(114)
Male
(97)
Adult
(84)
Middle Aged
(84)
Aged
(67)
Oncology
(57)
Animals
(48)
Neurosciences & Neurology
(39)
Lung Neoplasms - Drug Therapy
(37)
Respiratory System
(37)
Pharmacology. Drug Treatments
(32)
Pneumology
(31)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(30)
Lung Neoplasms - Pathology
(29)
Life Sciences
(28)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC)

A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson's index

Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours

Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04–IFCT 00-01

Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes

Survival of Patients With Resected N2 Non–Small-Cell Lung Cancer: Evidence for a Subclassification and Implications

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials

Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer

Gemcitabine–docetaxel versus cisplatin–vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin

Phase II Comparator Study of Oral Versus Intravenous Topotecan in Patients With Chemosensitive Small-Cell Lung Cancer

Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy should prophylactic cranial irradiation be reconsidered?

Etoposide Plus Cisplatin With or Without the Combination of 4′-Epidoxorubicin Plus Cyclophosphamide in Treatment of Extensive Small-Cell Lung Cancer: a French Federation of Cancer Institutes Multicenter Phase III Randomized Study

Routine molecular profiling of cancer: results of a one-year nationwide program of the French CooperativeThoracic Intergroup (IFCT) for advanced non-small cell lung cancer (NSCLC) patients

Second-line treatment for advanced non-small cell lung cancer: A systematic review

Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: prospective study in 621 patients

Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

Aneuploidy and prognosis of non-small-cell lung cancer: a meta-analysis of published data

Combination of chemotherapy without platinum compounds in the treatment of advanced non-small cell lung cancer: A systematic review of phase III trials

Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer

Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer

Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer

Long Term Analysis of Survival in the European Randomized Trial Comparing Vinorelbine/Cisplatin to Vindesine/Cisplatin and Vinorelbine Alone in Advanced Non‐Small Cell Lung Cancer

Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer

Suchergebnisse filtern